Scientists discover a cause of lupus and a possible way to reverse it

Two cellular defects appear to drive disease in lupus

2024-07-10

(Press-News.org) · Lupus is an autoimmune disease affecting more than 1.5 million people in the U.S.

· Until now, the causes of this disease remained unclear
· Scientists are working to expand research into novel treatment

CHICAGO --- Northwestern Medicine and Brigham and Women’s Hospital scientists have discovered a molecular defect that promotes the pathologic immune response in systemic lupus erythematosus (known as lupus) and show that reversing this defect may potentially reverse the disease.

Lupus affects more than 1.5 million people in the U.S. Until this new study, the causes of this disease were unclear. Lupus can result in life-threatening damage to multiple organs including the kidneys, brain and heart. Existing treatments often fail to control the disease, the study authors said, and have unintended side effects of reducing the immune system’s ability to fight infections.

“Up until this point, all therapy for lupus is a blunt instrument. It’s broad immunosuppression,” said co-corresponding author Dr. Jaehyuk Choi, associate professor of dermatology at Northwestern University Feinberg School of Medicine and a Northwestern Medicine dermatologist. “By identifying a cause for this disease, we have found a potential cure that will not have the side effects of current therapies.”

“We’ve identified a fundamental imbalance in the immune responses that patients with lupus make, and we’ve defined specific mediators that can correct this imbalance to dampen the pathologic autoimmune response,” said co-corresponding author Dr. Deepak Rao, an assistant professor of medicine at Harvard Medical School and a rheumatologist at Brigham and Women’s Hospital and co-director of its Center for Cellular Profiling.

In a study to be published in Nature on July 10, the scientists report a new pathway that drives disease in lupus. There are disease-associated changes in multiple molecules in the blood of patients with lupus. Ultimately, these changes lead to insufficient activation of a pathway controlled by the aryl hydrocarbon receptor (AHR), which regulates cells’ response to environmental pollutants, bacteria or metabolites. Insufficient activation of AHR results in too many disease-promoting immune cells, called the T peripheral helper cells, that promote the production of disease-causing autoantibodies.

To show this discovery can be leveraged for treatments, the investigators returned the aryl hydrocarbon receptor-activating molecules to blood samples from lupus patients. This seemed to reprogram these lupus-causing cells into a cell called a Th22 cell that may promote wound healing from the damage caused by this autoimmune disease.

“We found that if we either activate the AHR pathway with small molecule activators or limit the pathologically excessive interferon in the blood, we can reduce the number of these disease-causing cells,” said Choi, also the Jack W. Graffin Professor at Feinberg. “If these effects are durable, this may be a potential cure.”

Choi, Rao and colleagues next want to expand their efforts into developing novel treatments for lupus patients. They are now working to find ways to deliver these molecules safely and effectively to people.

Other Northwestern authors are first author Calvin Law, Arundhati Pillai, Brandon Hancock and Dr. Judd Hultquist. Brigham and Women’s Hospital authors include Vanessa Sue Wacleche, Ye Cao, John Sowerby, Alice Horisberger, Sabrina Bracero, Ifeoluwakiisi Adejoorin, Eilish Dillon, Daimon Simmons, Elena Massarotti, Karen Costenbader, Michael Brenner and James Lederer.

The title of the article is “Interferon subverts an AHR-JUN axis to promote CXCL13+ T cells in lupus.”

The research was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases grants K08 AR072791, P30 AR070253, R01 AR078769 and P30 AR075049; National Institute of Allergy and Infectious Diseases grants R01 AI176599, P30 AI117943, R01 AI165236 and U54 AI170792; National Cancer Institute grants F31 CA268839 and CA060553, all of the National Institutes of Health (NIH); and NIH Director’s New Innovator Grant 1DP2AI136599-01, and grants from Lupus Research Alliance, Burroughs Wellcome Fund, Bakewell Foundation, Leukemia and Lymphoma Society and American Cancer Society.

END

ELSE PRESS RELEASES FROM THIS DATE:

Few U.S. adults use nicotine pouches, study finds

2024-07-10

A new study found that the prevalence of nicotine pouch use was low in U.S. adults despite a 641% increase in sales of the products between 2019 and 2022. Researchers say the findings raise questions about who is using the millions of nicotine pouches sold in the U.S. and why. Nicotine pouches, a new commercial tobacco product, contain a crystalline powder with nicotine, flavorings (including fruit, mint or candy) and other additives. They do not cause respiratory harm and are perceived by some as an alternative to help adults who smoke tobacco quit. ...

Surprise discovery with big scientific potential

2024-07-10

An unexpected find has enabled important progress to be made in the battle against harmful bacteria. An international team of researchers, led by Professor Peter Fineran from the University of Otago, investigated a particular protein used by bacteria-infecting viruses, known as phages. Research into this microscopic arms race between bacteria and phages is important as it can lead to alternatives to antibiotics. Published in prestigious international journal Nature, the study analysed a protein phages use when deploying anti-CRISPR, their method of blocking the CRISPR–Cas immune system of bacteria. Lead ...

The plague may have caused the downfall of the Stone Age farmers

2024-07-10

Ancient DNA from bones and teeth hints at a role of the plague in Stone Age population collapse. Contrary to previous beliefs, the plague may have diminished Europe's populations long before the major plague outbreaks of the Middle Ages, new research shows. In the 14th century Europe, the plague ravaged the population during the so-called 'Black Death,' claiming the lives of nearly a third of the population. But the plague arrived in Scandinavia several thousand years earlier, and despite several theories suggesting otherwise, the plague might have caused an epidemic, according to new research from ...

When there’s money to lose, phone usage while driving drops

2024-07-10

PHILADELPHIA— To make someone put their phone down while driving, show them the money—with a catch, according to new research published in JAMA Open. When a group of auto insurance customers were tempted with a cash incentive—and regular feedback letting the driver know how they were doing compared to other drivers trying to reduce their phone time—handheld phone use dropped significantly, a team at the Perelman School of Medicine at the University of Pennsylvania found. The researchers examined several different strategies ...

Astronomers find missing link in massive black hole formation

2024-07-10

Omega Centauri is a spectacular collection of 10 million stars, visible as a smudge in the night sky from Southern latitudes. Through a small telescope, it looks no different from other so-called globular clusters; a spherical stellar collection so dense towards the center that it becomes impossible to distinguish individual stars. But a new study, led by researchers from the University of Utah and the Max Planck Institute for Astronomy, confirms what astronomers had argued about for over a decade: Omega Centauri contains a central black hole. The black hole appears to be the missing link between its stellar ...

Researchers build first-ever molecular atlas of blood vessel pathways in the human brain, across early brain development, adulthood and disease

2024-07-10

An international consortium of researchers led by University Health Network (UHN) in Toronto and University of Zurich have built the first-ever molecular atlas of the human brain vasculature at single-cell resolution, spanning from early development to adulthood and through disease stages such as brain tumours and brain vascular malformations. The international consortium includes research teams from UHN’s Krembil Brain Institute, Donald K. Johnson Eye Institute, Toronto General Hospital Research Institute and Princess Margaret Cancer Centre, the University of Toronto’s Donnelly Centre, Mount Sinai Hospital’s Lunenfeld-Tanenbaum ...

Antiferromagnetic phase transition observed in fermionic Hubbard quantum simulator

2024-07-10

In a study published online in Nature, a research team led by Prof. PAN Jianwei, Prof. CHEN Yuao, and Prof. YAO Xingcan from the University of Science and Technology of China (USTC) of the Chinese Academy of Sciences has, for the first time, observed the antiferromagnetic phase transition within a large-scale quantum simulator of the fermionic Hubbard model (FHM). This study highlights the advantages of quantum simulation. It marks an important first step towards obtaining the low-temperature phase diagram of the FHM and understanding the role of quantum magnetism in the mechanism of high-temperature ...

A drug that lowers blood lipids could help treat the world’s most common liver disease

2024-07-10

The University of Barcelona has led a study that suggests using the drug known as pemafibrate to treat liver disease associated with metabolic disorders, the most common liver pathology in the world, which affects one in four people. The drug has long been marketed in Japan for another use: improving blood lipid levels in patients with hyperlipidaemia, a common condition in diabetics. Now, however, it could help address this serious liver disease, which still has no specific treatment. The study, carried out on laboratory animal models and published in the journal Biomedicine & Pharmacotherapy, was conducted by a team led by Professor Juan ...

Ochsner, AJMC® partner for conference on value-based care on July 25 in New Orleans

2024-07-10

NEW ORLEANS – Ochsner Health’s Healthy State initiative, in partnership with The American Journal of Managed Care, will host a free conference on value-based care from 3:30-7 p.m. on Thursday, July 25 at The Westin New Orleans hotel in Louisiana. Registration and program details are available here for “Healthy State: Know It, Own It, Live It: Creating a Thriving Louisiana Through Innovation in Value-Based Care.” The event is open to the public, medical professionals, health policy experts and community organizers. Organized ...

NIH funds consortium to accelerate development of new TB treatments

2024-07-10

A new consortium co-led by Weill Cornell Medicine, has been awarded a five-year, $31 million grant from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases to accelerate the development of faster, more effective treatment regimens for tuberculosis (TB). Investigators at the University of California, San Francisco; Johns Hopkins Medicine; and Vanderbilt University Medical Center comprise the other co-leads. The Preclinical Design and Clinical Translation ...

The Lancet Global Health: Modelling suggests climate change could drive millions globally into physical inactivity by 2050 and be linked to an estimated half a million premature deaths

Scientists discover a cause of lupus and a possible way to reverse it

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: